CTR20262952 Bevacizumab biosimilar (Tot Biopharm) Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262952 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 5 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262952 is a hot trial to watch
Hepatocellular Carcinoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262952 is notable because it evaluates Bevacizumab biosimilar (Tot Biopharm) in a Phase 1/2 design sponsored by CSPC Megalith Biopharmaceutial Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262952 |
| Official title | SYS6090注射液治疗肝细胞癌的Ib/Ⅱ期研究 |
| Phase / status | Phase 1/2 / 进行中 （尚未招募） |
| Intervention | Bevacizumab biosimilar (Tot Biopharm) |
| Sponsor | CSPC Megalith Biopharmaceutial Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 直至疾病进展、出现不可耐受的毒性、开始新的抗肿瘤治疗、退出试验、失访或死亡 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 1/2 study of Bevacizumab biosimilar (Tot Biopharm) in Hepatocellular Carcinoma.
Allocation is 随机化, masking is 开放, and the intervention model is 析因设计. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (直至疾病进展、出现不可耐受的毒性、开始新的抗肿瘤治疗、退出试验、失访或死亡) — Ib期：剂量限制性毒性；不良事件、严重不良事件等的发生率与严重程度
- Primary endpoint (直至疾病进展、出现不可耐受的毒性、开始新的抗肿瘤治疗、退出试验、失访或死亡) — Ib期：II期推荐剂量和最大耐受剂量
- Primary endpoint (直至疾病进展、出现不可耐受的毒性、开始新的抗肿瘤治疗、退出试验、失访或死亡) — II期：研究者评估的疾病缓解率
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Bevacizumab biosimilar (Tot Biopharm) is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: CSPC Megalith Biopharmaceutial Co., Ltd. is resolved to a normalized organization record in Shijiazhuang, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262952 provides a focused lens on Hepatocellular Carcinoma development. Its value will be determined by whether Bevacizumab biosimilar (Tot Biopharm) can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
